Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerUsing germline genomics to individualize pediatric cancer treatmentsSystemic therapies for pancreatic cancer--the role of pharmacogeneticsPharmacogenomics of chemotherapeutic susceptibility and toxicityUGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyPharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsIrinotecan pharmacogenomicsMultidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical applicationFlavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol dispositionStrain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileumThe role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in ratsEffect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic studyChemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management.Effects of methimazole on the elimination of irinotecan.Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between Uzbek and Japanese populationsEffects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on IrinotecPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsAssociation of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patientsUrinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Metabolic pathways of the camptothecin analog AR-67Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceClinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models.Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.The association of transporter genes polymorphisms and lung cancer chemotherapy responseAn internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patientsMethylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapyUGT1A1 is a major locus influencing bilirubin levels in African Americans.Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimensEffect of ABCC2 (MRP2) transport function on erythromycin metabolismContribution of tumoral and host solute carriers to clinical drug response.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis.Chemotherapy-induced neutropenia during adjuvant treatment for cervical cancer patients: development and validation of a prediction model.
P2860
Q26775949-A4783241-C2C0-4075-8F69-D4FF29964A9DQ27003261-F85FC350-B89E-424A-BA5E-08C777F57D67Q27021716-9D97F420-9751-48AB-AB31-B9B41E7E7BD5Q27025558-B08C8298-A377-4425-8208-6D02D0E15C62Q27851574-C442C874-F87F-403C-9D2C-EB53D3B4BE20Q28066096-30AF961A-8C66-47AF-8A73-A8B863BF67CDQ28287024-58BD9AB5-2352-4C5E-803D-A48F0515B7D5Q28468693-51768FF3-1928-4CFC-8317-81FEBD65646DQ28475976-8108F563-CDE1-47C2-A7C3-8D8A1EB8E0A5Q28478419-1F3FCD47-0B30-4C9A-9125-B12CB9C57B51Q28538671-BD615EEC-A492-4966-A262-B13EA894F924Q28744127-970DE7D1-1FC9-4037-8A73-98146BFD9547Q30318822-955F93E1-0478-4E6A-B4E6-7A20930DAFADQ33647853-414E5B09-C865-47E2-8129-813F0B27AF76Q33651706-8945678F-135B-41F9-AFBA-FA15B9F3CCA1Q33712655-369B1355-C7D1-479A-A357-F495B1A7A5D2Q33875931-2F1EF7B1-CF23-4155-A941-FD42E7614341Q34008793-8F803BAA-FB2B-4DE6-BC62-AD5756DE0366Q34026252-D5F439BA-7CEA-4841-AE22-D165B4A5750FQ34065294-C3738B66-4B85-4396-8951-63ABED7BAA28Q34071782-147395DD-AB8E-4085-B7B1-4CEA85945DD1Q34120416-492FCCCE-5F72-4027-969A-718A0DDE862FQ34391234-88C7F4C3-3430-4863-9202-4772F6AD2088Q34565071-8D280061-ED47-4A51-87CB-2AD4B96331BEQ34715481-4A45566D-30B8-4061-834A-E25167B9E9D7Q34774854-2FB0DF60-489A-4440-AB1B-02DEBD17B26AQ35050772-BD4015B9-EC07-4A61-A031-520694DA3F8AQ35099010-7C5C691A-4717-4856-86BF-3D417BB27F52Q35100986-BFA523AC-23A5-4CCF-884C-D2DFCFEA0877Q35124361-9FD05FB8-2B52-4E12-A19B-990EA4B670CFQ35603648-6FF0E231-A429-4308-80D8-E72206E0439AQ35623320-C2C83652-3434-437B-8C4E-F8804A5658C5Q35678729-0FBC10FC-EAA7-4313-97AA-4D097195F2C1Q35837634-0BF7EDD3-3216-4C4E-A2F0-97297CC2201EQ35887458-6D877B4D-E13A-4FFD-B4CB-83A6C3564926Q35902300-50AD085B-41F3-4337-AD2F-165213234347Q35946876-630DE92D-0AAB-4269-AA4B-D6392110BB21Q36035404-AE922991-94CD-4517-B2CD-213F9820D2AAQ36043023-BC1DC2E0-677A-4ACD-ACF4-BFDB5DC65FF6Q36046284-1BD26B35-07A8-4CC5-809C-4984E4D30E8A
P2860
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@ast
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@en
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@nl
type
label
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@ast
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@en
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@nl
prefLabel
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@ast
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@en
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@nl
P2093
P2860
P3181
P356
P1476
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics
@en
P2093
Deanna L Kroetz
Erin Schuetz
Federico Innocenti
Gary L Rosner
Jacqueline Ramírez
M Eileen Dolan
Mary Relling
Peixian Chen
P2860
P304
P3181
P356
10.1200/JCO.2008.20.6300
P407
P577
2009-06-01T00:00:00Z